Ahead of FDA adcomm, Pfizer, Moderna say COVID jab efficacy dipsPfizer and Moderna have both reported data that they say backs up the need for booster shots of Share XAhead of FDA adcomm, Pfizer, Moderna say COVID jab efficacy dipshttps://pharmaphorum.com/news/ahead-of-fda-adcomm-pfizer-moderna-say-covid-jab-efficacy-dips/
EU ‘negotiating with Valneva’ over COVID-19 vaccine contractThe European Commission is reportedly in advanced discussions with French biotech Valneva about picking up the contract to Share XEU ‘negotiating with Valneva’ over COVID-19 vaccine contracthttps://pharmaphorum.com/news/eu-negotiating-with-valneva-over-covid-19-vaccine-contract/
Astellas reports fourth death in halted gene therapy trialThere has been a fourth patient fatality in Astellas’ clinical trial of its AT132 gene therapy for the Share XAstellas reports fourth death in halted gene therapy trialhttps://pharmaphorum.com/news/astellas-reports-fourth-death-in-halted-gene-therapy-trial/
First FDA filing for Novartis’ latecomer PD-1 drug tislelizumabNovartis has filed for FDA approval of tislelizumab – a PD-1 inhibitor licensed from Chinese biotech BeiGene earlier Share XFirst FDA filing for Novartis’ latecomer PD-1 drug tislelizumabhttps://pharmaphorum.com/news/first-fda-filing-for-novartis-latecomer-pd-1-drug-tislelizumab/
NHS England starts largest ever trial of Galleri cancer blood testA blood test called Galleri that could detect dozens of different forms of cancer before symptoms appear will Share XNHS England starts largest ever trial of Galleri cancer blood testhttps://pharmaphorum.com/news/nhs-england-starts-largest-ever-trial-of-galleri-cancer-blood-test/
Cheap gout drug colchicine added to UK’s RECOVERY COVID-19 trialColchicine, a cheap and readily available anti-inflammatory drug used to treat diseases such as gout, is to be Share XCheap gout drug colchicine added to UK’s RECOVERY COVID-19 trialhttps://pharmaphorum.com/news/colchicine-added-to-uks-ground-breaking-recovery-covid-19-trial/
EU fines Teva and Cephalon €60.5m for ‘pay for delay’ schemeThe European Union has fined Teva and its neurology unit Cephalon €60.5 million for an elaborate “pay for Share XEU fines Teva and Cephalon €60.5m for ‘pay for delay’ schemehttps://pharmaphorum.com/news/eu-fines-teva-and-cephalon-e60-5m-for-pay-for-delay-scheme/
Concerns emerge after AZ’s lucky vaccine trial ‘mistake’AstraZeneca may have tried a positive spin on the trial mistake that led to the accidental discovery of Share XConcerns emerge after AZ’s lucky vaccine trial ‘mistake’https://pharmaphorum.com/news/concerns-emerge-after-azs-vaccine/
Novartis set to overcome $14 billion patent cliff say analystsNovartis’ pipeline is strong enough to overcome a $14 billion patent cliff as blockbuster drugs face generic competition Share XNovartis set to overcome $14 billion patent cliff say analystshttps://pharmaphorum.com/news/novartis-set-to-overcome-14-billion-patent-cliff-analyst/
